Depression

Following a long path to approval, gepirone hydrochloride extended-release tablets (Exxua) is the first FDA-approved medication with this novel mechanism of action for adults with MDD.

The ongoing clinical trial is also studying the drug’s efficacy in the treatment of MDD.

In this CME article, get a better understanding of bleeding risk associated with use of serotonin reuptake inhibitors (SRIs) and review research-informed literature on related bleeding complications in patients with cardiovascular and cerebrovascular disease.

“Are my other medications making my depression worse?” Researchers investigated associations between medications with potential depressive symptom adverse effects and the level of depressive symptoms in a large survey study.

From violence risk assessment in emergency departments to connections between bipolar disorder and substance use disorders, here are highlights from the week in Psychiatric Times.

What is new in research on psychedelics?

The investigators noted fast, clinically meaningful, and sustained improvements in symptoms of depression and related functional impairment.

Do SSRIs impact on the antidepressant efficacy of psilocybin? Researchers performed an open-label trial of single-dose psilocybin in patients with TRD who were taking SSRIs.

Medications for mental health and obesity: heavily stigmatized.

From the efficacy of adjunctive TMS for treatment-resistant major depression to a look at adult ADHD, here are highlights from the week in Psychiatric Times.

What is new in research on psychiatric care for Latinx patient populations?

Adjunctive rTMS for treatment-resistant depression? Researchers performed a meta-analysis of 19 randomized sham-controlled trials.

Investigators noted sustained improvement in depressive symptoms for up to 6.5 years.

The relationship of this key symptom of major depressive disorder and patient burden is not well understood. These two posters covered it.

“Among employed adults with TRD, esketamine nasal spray treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine extended-release treatment.”

From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.

How can augmenting conventional antidepressants with creatine monohydrate help patients with depression?

The drug’s developers respond to the FDA’s decision to deny approval and consider future directions for this indication.

From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.

The treatment was well-tolerated, and no serious treatment-emergent adverse effects were identified.

What is new in research on major depressive disorder?

You've heard about winter seasonal affective disorder, but what about summer?

Psychiatry: a field of medicine that is constantly evolving.

The FDA did not grant approval for the treatment for major depressive disorder.

In the largest study of its kind to date, researchers found promising results for subcutaneous ketamine for treatment resistant depression.